Faron Pharmaceuticals Oy (LON:FARN) Stock Price Passes Below 50 Day Moving Average - Should You Sell?

Key Points

• Faron Pharmaceuticals Oy's stock has dipped below its fifty-day moving average of GBX 209.87, trading as low as GBX 207.10 on Thursday.
• The company has a market cap of £284.61 million and a high debt-to-equity ratio of 922.55, which raises concerns about its financial health.
• Insider Markku Jalkanen recently sold 600,000 shares at an average price of GBX 310, indicating potential changes in investor sentiment as 31.82% of shares are held by insiders.

Faron Pharmaceuticals Oy (LON:FARN - Get Free Report)'s share price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 209.87 ($2.82) and traded as low as GBX 207.10 ($2.78). Faron Pharmaceuticals Oy shares last traded at GBX 210 ($2.82), with a volume of 69,951 shares.

Faron Pharmaceuticals Oy Price Performance

The company has a debt-to-equity ratio of 922.55, a quick ratio of 1.09 and a current ratio of 1.45. The company's fifty day moving average price is GBX 209.27 and its 200 day moving average price is GBX 201.13. The firm has a market capitalization of £295.35 million, a price-to-earnings ratio of -5.88 and a beta of 0.36.

Insider Activity at Faron Pharmaceuticals Oy

In related news, insider Markku Jalkanen sold 600,000 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of GBX 310 ($4.17), for a total transaction of £1,860,000 ($2,500,672.22). 31.82% of the stock is owned by insiders.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.